2-Methyl-4-((3aS,4S,6S)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)butan-2-ol
Ref. TR-M897550
100mg | Descatalogado | ||
250mg | Descatalogado | ||
500mg | Descatalogado |
Información del producto
Applications 2-Methyl-4-((3aS,4S,6S)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)butan-2-ol is an intermediate for the synthesis of 3-Hydroxy Bortezomib (H818150), which is a metabolite of Bortezomib (B675700); the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer.
References Nawrocki, S.T., et al.: Cancer Res., 65, 11510 (2005); Drahl, C.: Chem. and Eng. News, 87, 41 (2009)